Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Krystal Biotech (KRYS) Interest & Investment Income (2021 - 2026)

Krystal Biotech (KRYS) has disclosed Interest & Investment Income for 5 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 5.17% to $6.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.3 million through Dec 2025, down 4.34% year-over-year, with the annual reading at $28.2 million for FY2025, 4.84% down from the prior year.
  • Interest & Investment Income hit $6.9 million in Q4 2025 for Krystal Biotech, up from $6.6 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $7.6 million in Q1 2024 to a low of $30000.0 in Q2 2021.
  • Historically, Interest & Investment Income has averaged $4.3 million across 5 years, with a median of $5.7 million in 2023.
  • Biggest five-year swings in Interest & Investment Income: surged 3784.29% in 2022 and later dropped 9.65% in 2025.
  • Year by year, Interest & Investment Income stood at $70000.0 in 2021, then soared by 3784.29% to $2.7 million in 2022, then surged by 172.49% to $7.4 million in 2023, then fell by 2.35% to $7.2 million in 2024, then dropped by 5.17% to $6.9 million in 2025.
  • Business Quant data shows Interest & Investment Income for KRYS at $6.9 million in Q4 2025, $6.6 million in Q3 2025, and $7.5 million in Q2 2025.